From Bench to Patient Care: Unlocking iPSC Potential Through Innovative Science and Strategic Partnerships
Abstract: In the iPSC derived cell therapy world, developing a suitable iPSC line is a key step, but not the only one.
Building Better Biologics: Overcoming Hurdles in Protein Therapy Manufacturing
This webinar will bring together industry leaders to discuss innovative strategies and practical solutions for manufacturing protein-based modality therapies.
Critical Role of Forced Degradation in Method Development of mAbs
Forced degradation studies are crucial for developing recombinant monoclonal antibody therapeutics, aiding in everything from early manufacturability checks to comparability assessments before and after marketing approval.
Catalent Biologics Analytical Services Capability Overview
Join Vincy Abraham, Director of Biologics Analytical Services, to discover how Catalent leverages its extensive expertise and capabilities to deliver tailored solutions to meet specific analytical needs for your biotherapeutics.
Leveraging Platform Processes For Developing And Accelerating Novel Gene And Cancer Therapeutics
This year, the long-awaited FDA draft guidance for Platform Technology Designation Program was launched. This critical guidance allows drug developers to leverage Platform Technology data in approved drugs if similar “platforms” are used, accelerating the approval process and therapies to patients. In this webinar, George Buchman will discuss Catalent’s approach to platform processes as well as securing an integrated supply chain.